Imugene Ltd Reports First Complete Response in Azer Cel BTKi Cohort
Imugene's azer-cel has achieved its first complete response in the BTKi combination cohort, with a Follicular Lymphoma patient who had previously failed BTKi therapy clearing disease at the Day 28 assessment — an early but significant signal in a US$12 billion market.
Key Takeaways
- The first evaluable patient in Imugene's azer-cel concurrent BTKi cohort achieved a complete response at Day 28 — a patient with Follicular Lymphoma who had previously failed BTKi therapy, representing one of the most difficult-to-treat populations in B-cell malignancies.
- The BTKi combination cohort targets a global market worth approximately US$12.0 billion in 2025, with a significant patient subset developing resistance to standard BTKi therapy and having limited remaining treatment options.
- Four patients have now been dosed in the BTKi cohort, including the first mantle cell lymphoma patient, with enrolment continuing across ten US and five Australian sites.
- Azer-cel's off-the-shelf allogeneic design means it is ready for administration within days, compared to the three-to-six-week manufacturing lead time required for autologous CAR T products — a practical advantage in this urgent patient population.
- Investors should treat this as an early but meaningful signal: the company has explicitly noted this is single-patient, early-stage data, and efficacy conclusions will depend on results as the broader dataset develops.
Breaking ASX Alerts Direct to Your Inbox
Join +20,000 subscribers receiving alerts.
Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.
- Breaking ASX announcements delivered within minutes
- Alerts delivered with expert analysis
- Optional text alert for subscribers
- No spam policy, unsubscribe any time
About the Publisher
StockWire X delivers fast, reliable, and actionable insights into significant developments across global markets, with coverage spanning technology, biotechnology, healthcare, financials, and emerging industries. Our mission is to provide clear, data-driven content that empowers investors to identify opportunities and make informed decisions ahead of the market.
Our network spans key financial and investment hubs worldwide, ensuring subscribers receive timely updates on market-moving announcements, news, macroeconomic trends, and corporate developments.
Use of Technology
We harness advanced technologies to enhance the speed, accuracy, and relevance of our reporting.
While technology accelerates our workflow, every piece of content is selected, validated, and published by human professionals, in accordance with best practices for accuracy, transparency, and investor value. This hybrid approach ensures speed without compromising editorial integrity.
Feedback and Accuracy
We are committed to accuracy and fairness in our reporting. If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.
Disclaimer
StockWire X provides readers with access to market news, educational content, and commentary from financial services professionals, industry experts, and companies (“Contributors”).
StockWire X does not hold an Australian Financial Services Licence (AFSL) and relies on the exemption available under section 911A(2)(eb) of the Corporations Act 2001 (Cth) in respect of any financial product advice provided.
Any advice or information published by StockWire X is general in nature only and has been prepared without taking into account your personal objectives, financial situation, or needs. Before acting on any information, you should consider whether it is appropriate for your circumstances and seek independent, licensed financial advice. You should also obtain and read any relevant Product Disclosure Statement (PDS) or other offer document before making an investment decision.
StockWire X makes no guarantee as to the accuracy, completeness, or timeliness of the information provided, and accepts no responsibility for any loss arising from reliance on it. All content is published in good faith for informational purposes only.
Disclosure
StockWire X may have commercial relationships with some contributors or companies mentioned in our content. Any such relationships will be disclosed where relevant.
If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.